Illumina, Inc. (NASDAQ:ILMN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
Meeting) was held on May 30, 2017, at which the company’s
stockholders voted upon the following proposals:
|
1.
|
The election of Caroline Dorsa, Robert Epstein, and Philip
Schiller to our Board of Directors to hold office for three years until the annual meeting of stockholders in the year 2020. This proposal was approved. |
|
2.
|
The ratification of the appointment of Ernst Young LLP as the
Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017. This proposal was approved. |
|
3.
|
On an advisory basis, approval of the compensation paid to
the Company’s named executive officers as disclosed in the Company’s Proxy Statement for the Annual Meeting. This proposal was approved. |
|
4.
|
The advisory vote on the frequency of future advisory votes
to approve the compensation of the Companys named executive officers as disclosed in the Companys future proxy statements. The alternative of every year received the highest number of votes. |
|
5.
|
Approval of an amendment to the Companys certificate of
incorporation removing certain supermajority voting requirements. This proposal was approved. |
person or by proxy representing 134,705,120 shares of the
Company’s common stock voted on the proposals presented as
follows:
|
Proposal 1
|
Votes regarding the election of three director nominees were:
|
|
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
||||
|
Caroline Dorsa
|
123,855,738
|
945,076
|
51,695
|
9,852,611
|
||||
|
Robert Epstein
|
123,925,611
|
872,809
|
54,089
|
9,852,611
|
||||
|
Philip Schiller
|
124,456,707
|
339,574
|
56,228
|
9,852,611
|
|
Proposal 2
|
Votes regarding the ratification of the appointment of Ernst
Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017, were: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
133,288,215
|
1,263,152
|
153,753
|
|
|
Proposal 3
|
Votes regarding the approval, on an advisory basis, of the
compensation paid to the Company’s named executive officers as disclosed in the Company’s Proxy Statement for the Annual Meeting were: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
121,986,926
|
2,062,366
|
803,217
|
9,852,611
|
|
Proposal 4
|
Votes regarding the advisory vote on the frequency of future
advisory votes to approve the compensation paid to the Companys named executive officers |
|
1 Year
|
2 Years
|
3 Years
|
Abstain
|
|
113,875,744
|
65,521
|
10,826,857
|
84,387
|
|
Proposal 5
|
Votes regarding the approval of an amendment to the Companys
certificate of incorporation removing certain supermajority voting requirements: |
|
For
|
Against
|
Abstain
|
Broker Non-Votes
|
|
124,530,099
|
125,817
|
196,593
|
9,852,611
|
About Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets. Illumina, Inc. (NASDAQ:ILMN) Recent Trading Information
Illumina, Inc. (NASDAQ:ILMN) closed its last trading session up +3.78 at 177.36 with 1,443,302 shares trading hands.
